These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32375387)

  • 1. Cnf1 Variants Endowed with the Ability to Cross the Blood-Brain Barrier: A New Potential Therapeutic Strategy for Glioblastoma.
    Colarusso A; Maroccia Z; Parrilli E; Germinario EAP; Fortuna A; Loizzo S; Ricceri L; Tutino ML; Fiorentini C; Fabbri A
    Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32375387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CTX-CNF1 Recombinant Protein Selectively Targets Glioma Cells In Vivo.
    Vannini E; Mori E; Tantillo E; Schmidt G; Caleo M; Costa M
    Toxins (Basel); 2021 Mar; 13(3):. PubMed ID: 33800135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiology of glioma: a Rho GTPase-activating protein reduces tumor growth and spares neuron structure and function.
    Vannini E; Olimpico F; Middei S; Ammassari-Teule M; de Graaf EL; McDonnell L; Schmidt G; Fabbri A; Fiorentini C; Baroncelli L; Costa M; Caleo M
    Neuro Oncol; 2016 Dec; 18(12):1634-1643. PubMed ID: 27298309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of motor deficits in glioma-bearing mice: impact of CNF1 therapy at symptomatic stages.
    Vannini E; Maltese F; Olimpico F; Fabbri A; Costa M; Caleo M; Baroncelli L
    Oncotarget; 2017 Apr; 8(14):23539-23550. PubMed ID: 28212563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bacterial protein toxin, cytotoxic necrotizing factor 1 (CNF1) provides long-term survival in a murine glioma model.
    Vannini E; Panighini A; Cerri C; Fabbri A; Lisi S; Pracucci E; Benedetto N; Vannozzi R; Fiorentini C; Caleo M; Costa M
    BMC Cancer; 2014 Jun; 14():449. PubMed ID: 24939046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.
    Dréan A; Lemaire N; Bouchoux G; Goldwirt L; Canney M; Goli L; Bouzidi A; Schmitt C; Guehennec J; Verreault M; Sanson M; Delattre JY; Mokhtari K; Sottilini F; Carpentier A; Idbaih A
    J Neurooncol; 2019 Aug; 144(1):33-41. PubMed ID: 31197598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial Toxins and Targeted Brain Therapy: New Insights from Cytotoxic Necrotizing Factor 1 (CNF1).
    Tantillo E; Colistra A; Vannini E; Cerri C; Pancrazi L; Baroncelli L; Costa M; Caleo M
    Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29857515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
    Hall WA; Vallera DA
    Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.
    Bi J; Khan A; Tang J; Armando AM; Wu S; Zhang W; Gimple RC; Reed A; Jing H; Koga T; Wong IT; Gu Y; Miki S; Yang H; Prager B; Curtis EJ; Wainwright DA; Furnari FB; Rich JN; Cloughesy TF; Kornblum HI; Quehenberger O; Rzhetsky A; Cravatt BF; Mischel PS
    Cell Rep; 2021 Nov; 37(5):109957. PubMed ID: 34731610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Rac GTPase-activating bacterial protein toxin CNF1 induces analgesia up-regulating mu-opioid receptors.
    Pavone F; Luvisetto S; Marinelli S; Straface E; Fabbri A; Falzano L; Fiorentini C; Malorni W
    Pain; 2009 Sep; 145(1-2):219-29. PubMed ID: 19608345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bacterial protein CNF1 as a new strategy against Plasmodium falciparum cytoadherence.
    Messina V; Loizzo S; Travaglione S; Bertuccini L; Condello M; Superti F; Guidotti M; Alano P; Silvestrini F; Fiorentini C
    PLoS One; 2019; 14(3):e0213529. PubMed ID: 30845261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic necrotizing factor type 1 delivered by outer membrane vesicles of uropathogenic Escherichia coli attenuates polymorphonuclear leukocyte antimicrobial activity and chemotaxis.
    Davis JM; Carvalho HM; Rasmussen SB; O'Brien AD
    Infect Immun; 2006 Aug; 74(8):4401-8. PubMed ID: 16861625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
    Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
    Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.
    Salphati L; Heffron TP; Alicke B; Nishimura M; Barck K; Carano RA; Cheong J; Edgar KA; Greve J; Kharbanda S; Koeppen H; Lau S; Lee LB; Pang J; Plise EG; Pokorny JL; Reslan HB; Sarkaria JN; Wallin JJ; Zhang X; Gould SE; Olivero AG; Phillips HS
    Clin Cancer Res; 2012 Nov; 18(22):6239-48. PubMed ID: 22992516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
    Wang D; Wang C; Wang L; Chen Y
    Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of KATP channels increases anticancer drug delivery to brain tumors and survival.
    Ningaraj NS; Sankpal UT; Khaitan D; Meister EA; Vats T
    Eur J Pharmacol; 2009 Jan; 602(2-3):188-93. PubMed ID: 19027730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma.
    Ciesielski MJ; Bu Y; Munich SA; Teegarden P; Smolinski MP; Clements JL; Lau JYN; Hangauer DG; Fenstermaker RA
    J Neurooncol; 2018 Dec; 140(3):519-527. PubMed ID: 30238350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic necrotizing factor 1 contributes to Escherichia coli meningitis.
    Wang MH; Kim KS
    Toxins (Basel); 2013 Nov; 5(11):2270-80. PubMed ID: 24284829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.